MedTrace Logo

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

NCT05454358 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-15

No results posted yet for this study

Summary

Aim to investigate the effect of Letrozole as maintenance after adjuvant treatment on the prognosis of post-operative endometrial cancer patients with non-specific molecular profile.

Conditions

Interventions

DRUG

Letrozole 2.5mg

Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy

Sponsors & Collaborators

  • Obstetrics & Gynecology Hospital of Fudan University

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaojun Chen, Ph.D, M.D · Obstetrics & Gynecology Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05454358 on ClinicalTrials.gov